BeiGene Ltd.

Brendan, a Ph.D. in organic synthesis from Stanford, worked at Merck and biotech start-ups before co-founding 1200 Pharma. He remains an investor in biotech stocks and holds positions in BGNE and ABBV. This article is his own opinion and not investment advice.

Life sciences sector resilient despite challenges; significant investments in ADCs, CGTs, AI, and CDMOs. ADCs and CGTs driving growth, with China leading in clinical trials and innovation. AI transforming drug discovery and clinical trials. APAC region dominating clinical trials, especially in oncology. China's biopharma sector booming, attracting global investments. CDMOs adopting digital revolution and AI for agile manufacturing. BIOSECURE Act impacting Chinese biotech companies, benefiting Indian CDMOs.

The article discusses the importance of enabling JavaScript for optimal app performance.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.

The European Commission approves BeiGene’s PD-1 inhibitor Tevimbra, in combination with chemotherapy, for first-line treatment of oesophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. Tevimbra, targeting the PD-1 receptor, enhances T cell activity to attack tumor cells, showing improved median overall survival in Phase III trials.

BeiGene’s Tevimbra (tislelizumab) approved by EC for first-line treatment of advanced gastric or oesophageal cancer in combination with chemotherapy. Based on RATIONALE-305 and RATIONALE-306 trials, Tevimbra showed reduced risk of death in PD-L1 expressing patients.

The European Commission approves BeiGene’s PD-1 inhibitor Tevimbra, in combination with chemotherapy, as a first-line treatment for oesophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. This expands Tevimbra’s EU indication, previously approved for advanced or metastatic ESCC after chemotherapy. Data from Phase III trials show improved median overall survival with Tevimbra plus chemotherapy, particularly in PD-L1-expressing cancers.

The European Commission has approved tislelizumab plus chemotherapy for first-line treatment of esophageal squamous cell carcinoma and gastroesophageal junction adenocarcinoma, based on results from the RATIONALE-306 and RATIONALE-305 trials.